

EuMAR Final Dissemination Conference



Brussels, Friday 12 December 2025



Co-funded by the European Union.

Project: 101079865 — EuMAR — EU4H-2021-PJ2

European Medically Assisted Reproduction registry Final Dissemination Conference

Welcome and opening remarks

Carlos Calhaz-Jorge



Co-funded by the European Union.

Project: 101079865 — EuMAR — EU4H-2021-PJ2




Data collection in EU member states: overview on types of registry



MAR data collected in EU countries (2021)

- Complete cycle-by-cycle data
- Incomplete cycle-by-cycle data
- Complete summary data
- Incomplete summary data
- No data collection



Project Steering Committee



Cristina Magli
WP3 Leader



Jesper Smeenk
WP4 and WP7 Leader



Christine Wyns
WP5 Leader



Christian De Geyter
WP6 Leader

Project Support Team



Elena Achotegui Sebastian



Veerle Gossens



Johanna Tassot



Laura Rossignoli



Nathalie Vermeulen



Ask your questions



Code: [#EuMAR25](#)





Session 1:

The origins of EuMAR

Original goals, rationale, policy context


Christian De Geyter

Brussels, Friday 12 December 2025




Co-funded by the European Union.

Project: 101079865 — EuMAR — EU4H-2021-PJ2



Registries in infertility treatments



Common goals:

- Routinely **collect data**
- **Inform stakeholders** on:
 - Accessibility
 - Effectiveness
 - Safety

Value of registries



- as an extension to evidence resulting from randomised clinical trials -



- Real-world **evidence of day-to-day clinical care**
- **Large cohorts** allowing for detection of **rare Adverse Events (AE) or Reactions (AR)**
- **Extended period of observation**
- **Tools for surveillance/vigilance:**
 - Benchmark towards **higher performance** and **risk reduction** or **prevention**
 - Analyse trends to assess **impact of changes in treatment, policies and demographics on outcomes**
 - Inform on countries' **self-sufficiency of care**

International registries: challenges

Different **data collection systems** and **organisations** that manage data

- Unified approach
- Unique European platform

Different **measurement properties**

- Harmonised data

Different **regulations** (e.g. mandatory reporting, socio-economical issues)

- Legal basis (SoHO Regulation)

Different **technological evolutions/innovations**

- Timely uptake

Sequential treatment → **cross-border care/exchange** of biological material

- Identification of procedures linked to the same patient/treatment cycle
- Individual reproductive care code
- Longitudinal follow-up over long periods



European IVF Monitoring (EIM) Consortium



The EIM Consortium collects ART data
(on a **voluntary basis**) on:



Techniques:

- **Assisted Reproductive Technologies (ART)** : In-Vitro Fertilisation – Intracytoplasmic Sperm Injection (IVF – ICSI)
- **Intrauterine Insemination (IUI)**
- **Within couple use** and/or using **third-party donations**
- **Fertility preservation**
- **FET (Frozen Embryo Transfer)** and **FOR (Frozen Oocyte Replacement)**
- **ED (Egg Donation)** and **Embryo donation**
- **PGT (Preimplantation Genetic Testing)**
- **IVM (In Vitro Maturation)**



European IVF Monitoring (EIM) Consortium



The **EIM registry**
is the largest
European
registry led by
experts in the
field

Some
countries have
a *delay* in
sending in
(complete)
data


In many
countries,
reporting is
voluntary

23 mandatory
/12 voluntary*




European IVF Monitoring (EIM)



- cross-sectional data sets, as published annually, have helped to reveal crucial trends in ART -



European IVF Monitoring (EIM)



Data collection in MAR



Highly variable among countries

Summary-level data <ul style="list-style-type: none">• Only aggregate information is reported.	Cycle-level data <ul style="list-style-type: none">• Each cycle is reported individually including its characteristics (e.g. number of oocytes, embryos) and outcome<ul style="list-style-type: none">→ Higher quality data→ Allows calculation of summary data→ Possibility to link with other datasets (e.g. birth registry for monitoring of long-term outcomes of ART)
Retrospective	Prospective <ul style="list-style-type: none">• Short time frame for reporting a limited number of data at cycle initiation
Voluntary <ul style="list-style-type: none">• Selection bias and incompleteness.	Compulsory <ul style="list-style-type: none">• Enforced by legislation/certification for ART practice

ESHRE aims at increasing the value of MAR registries by:

- addressing the **lack of standardisation of definitions** and **harmonisation of metrics**
- establishing a **web-based prospective cycle-by-cycle registry** of high-quality data towards:
 - increased surveillance and vigilance
 - interconnection with other registries (**cross-entity registry**)
- achieving a **flexible data flow** that **meets the needs of all stakeholders**

→ EuMAR project

Strengthening the legal basis for mandatory data collection in MAR
paves the way to *acquire, use* and *share* data with all stakeholders.

The EuMAR project



Aim of the project

To establish the first 'overarching' European, standardised, web-based data registry, containing high-quality cycle-by-cycle data entries from medical professionals across the EU, facilitating data sharing for open science across institutes and allowing the longitudinal and cross-border follow up of medically-assisted reproduction (MAR) data.

- **Type of action:** EU4H-PJG
- **Project coordinator:** European Society of Human Reproduction and Embryology (ESHRE)
- **Timeframe:** start 01 January 2023, running for 3 years
- **Funding programme:** EU4Health

The EuMAR project - Objectives



'overarching' European, standardised, web-based data registry, containing high-quality cycle-by-cycle data entries from medical professionals across the EU.

This registry can facilitate data sharing for open science across institutes and allow the longitudinal and cross-border follow up of MAR data.

SO1: Data flow

Develop a **flexible data flow model** that can be implemented in the local contexts of all Member States


SO2: Core parameters

Develop a **list of core, standardised parameters** with corresponding definitions on which data is to be collected


SO3: Technical solution

Establish a transnational web-based data registry to collect and store cycle-by-cycle and case-based harmonised **MAR data**, including a unique **Individual Reproductive Care Code (IRCC)** for MAR patients/donors

The EuMAR project



Policy context



Stakeholder landscape and engagement


M. Cristina Magli

Brussels, Friday 12 December 2025




Co-funded by the European Union.

Project: 101079865 — EuMAR — EU4H-2021-PJ2



Stakeholder landscape



Stakeholder engagement focus



NCAs



MAR professionals



Patient representatives

Who they are →

Responsible for **authorisations**, surveillance, and compliance

Clinical teams and professional organisations

Fertility Europe & national patient associations

What they bring →

Legal mandate and regulatory authority

First-hand **clinical knowledge** and operational understanding

Insights into patient priorities and lived experience


What they benefit from →

EuMAR supports their role with harmonised, **high-quality data**

- Cumulative data calculations
- Cross-border data collection
- EuMAR KPIs
- Benchmarking
- Data for research harmonisation

EuMAR promotes **transparency** regarding success rates and treatment options


Stakeholder engagement strategy



Stakeholder engagement



EuMAR used a top-down approach, working **first with NCAs** (where applicable) **or with the organisations** responsible for MAR national data collection to...



Align with
national
priorities



Support consistent
implementation of
**data reporting
standards**




Obtain the
necessary
approvals for
data submission


Stakeholder engagement




EuMAR used a top-down approach, working **first with NCAs** (where applicable) **or with the organisations** responsible for MAR national data collection to...



This approach also allows for more **formal and coordinated communication** with clinics, ensuring that information and expectations flow clearly through established national channels



Barriers in stakeholder engagement



© GeoNames, Microsoft, Open Pla

- Cycle by cycle
- Aggregated
- No national registry

Powered by Bing

© GeoNames, Microsoft, Open Places, OpenStreetMap, TomTom

Data flows

Two data flows were established within EuMAR:

- A) For countries with a cycle-by-cycle national registry
- B) For countries without a cycle-by-cycle national registry

In each of these data flows, data could be submitted either **manually** through the EuMAR portal or **automatically** via an API (Application Programming Interphase).






What did **professionals** think about EuMAR

Success in stakeholder engagement

Willingness of MAR professionals to continue participating in EuMAR






What did **patients
think about EuMAR**




88%

of infertility patients would be **in favour of their data being shared** with a registry like EuMAR



76%

of infertility patients would have **more trust** in a clinic participating in EuMAR.



Success in stakeholder engagement

Engagement started for next countries to join the phase 2



Greece



Poland

Policy recommendations



EuMAR POLICY RECOMMENDATIONS

1. Raise patients' awareness on MAR data

2. Improve equitable access to fertility care

3. Collect MAR equality data

4. Ensure national mandatory reporting from all fertility clinics

5. Provide dedicated funding for EuMAR reporting

6. Make cycle-by-cycle MAR registries mandatory

7. Develop a legal framework for a gamete donor registry

WP3 members



Cristina Magli
WP Leader



Elena Achótegui Sebastián
Project Support



Johanna Tassot
Project Support



Thomas Ebner
WP3 Member



Thomas Strowitzki
WP3 Member



Edgar Mocanu
WP3 Member



Anja Pinborg
WP3 Member



Carlos Plancha
WP3 Member



Nikolaos Polyzos
WP3 Member



Ioana Rugescu
WP3 Member

Basic concepts of EuMAR


Elena Achótegui Sebastián

Brussels, Friday 12 December 2025




Co-funded by the European Union.

Project: 101079865 — EuMAR — EU4H-2021-PJ2



Functioning of the EuMAR registry



Basic concepts of EuMAR



1. Cycle-by-cycle data

2. Cumulative outcome data

3. Cross-border data

4. IRCC

5. CSC


6. Data privacy

Cycle-by-cycle data



1. Cycle-by-cycle data


- In the EuMAR registry, data are collected for **every individual MAR treatment cycle**, rather than aggregating all cycles together.
- EuMAR is **the first Europe-wide registry** to collect cycle-by-cycle data on MAR treatments.





2. Cumulative outcome data

EuMAR aims to **report cumulative outcomes** by combining results per oocyte pick-up cycle, **rather than per individual transfer**, providing an overall view of the results achieved.





3. Cross-border data


One of the aims of the EuMAR registry is to **collect data on cross-border reproductive care** to better understand the extent of this phenomenon and to include cycles performed abroad in the cumulative calculations.



Individual Reproductive Care Code (IRCC)

4. IRCC


- The **Individual Reproductive Care Code (IRCC)** is a code assigned to each member of the couple (when applicable) to link all treatments within a clinic.
- The IRCC is **requested at the clinic level**.
- When sent to EuMAR, it is **encrypted** into the EuMAR code; the IRCC cannot be seen in EuMAR.



ClinicSwitch Code (CSC)



5. CSC





- The **ClinicSwitch Code (CSC)** is a QR code that a patient receives when following treatment in a different clinic.
- The CSC contains no medical data; it only serves as a **secure bridge** to follow patients that move between clinics.
- It needs to be **scanned** at the new clinic, which generates a new IRCC.

EuMAR structure

IRCC & CSC



CLINIC A



CYCLE 1 TRANSFER 1
TRANSFER 2
TRANSFER 3

CYCLE 2 TRANSFER 1
TRANSFER 2
TRANSFER 3




EuMAR structure





IRCC & CSC

CLINIC A



PATIENT REPORT

CLINICSWITCH CODES



CYCLE 1

TRANSFER 1
TRANSFER 2
TRANSFER 3

CYCLE 2

TRANSFER 1
TRANSFER 2
TRANSFER 3





EuMAR
by ESHRE

EuMAR structure



IRCC & CSC


CLINIC A



CYCLE 1 TRANSFER 1
TRANSFER 2
TRANSFER 3
CYCLE 2 TRANSFER 1
TRANSFER 2
TRANSFER 3





CLINICSWITCH CODES



PATIENT REPORT



CLINIC B





CYCLE 1 TRANSFER 1
TRANSFER 2
TRANSFER 3
CYCLE 2 TRANSFER 1
TRANSFER 2
TRANSFER 3

EuMAR structure



IRCC & CSC

CLINIC A




CYCLE 1 TRANSFER 1
TRANSFER 2
TRANSFER 3



CYCLE 2 TRANSFER 1
TRANSFER 2
TRANSFER 3



CLINICSWITCH CODES



CLINIC B



CYCLE 1 TRANSFER 1
TRANSFER 2
TRANSFER 3

CYCLE 2 TRANSFER 1
TRANSFER 2
TRANSFER 3



6. Data privacy

- EuMAR operates under the General Data Protection Regulation (**GDPR**).
- Data privacy in the EuMAR registry is based on a **set of features designed to protect data** about patients and clinics.




Data privacy for patient data




1

The **different codes and encryptions** ensure that no stakeholder has enough information to identify.



2

The **EuMAR parameters** collect data from which the patient cannot be identified.



3



Patient **informed consent** will be used as an additional security layer for data privacy.



Data privacy for clinic data



Clinics' data privacy is also ensured → KPIs from each clinic are only seen by that clinic (and their NCA where applicable).





Session 2:

Implementation, testing and lessons

Pilot study results: Technical validation and user experience, challenges encountered, and solutions adopted

Christian De Geyter

Brussels, Friday 12 December 2025



Co-funded by the European Union.

Project: 101079865 — EuMAR — EU4H-2021-PJ2



Pilot study design



Pilot study period


- IRCC requests and cycle data submission *July – December 2024*
- Pregnancy outcome data *January – September 2025*

Study population


- Individuals undergoing medically assisted reproduction or fertility preservation
- Oocyte donors

Prospectivity


IRCCs to be requested up to five days from start of treatment.




Pilot study design – data flows




Pilot study design – data flows



Pilot study design – data flows



Number of cycles per country



- Total number of cycles in participating centres during the pilot study period
- Cycles received by EuMAR

Number of unique patients/partners

In total, the 21,202 cycles involved:

- 15,477 unique main patients
- 12,691 unique partners

Cumulative data collection within the same institution:

- 4,310 main patients with two or more cycles


Inter-institutional data collection:

- 16 ClinicSwitch Codes (CSCs) requested within the pilot study period
- Only 4 CSCs (from 2 couples) scanned by another clinic
- Not a single patient with cycle data sent by more than one clinic

Timeliness of IRCC requests



Percentage of IRCC requests on time by cycle start month and IRCC request mode



IRCC request deadlines:

- For cycles with ovarian stimulation: within 5 days of stimulation start
- For cycles without ovarian stimulation: before the day of the procedure (e.g., IUI, FET)

Empty records (created Jul-Dec 2024)

	Number of IRCCs requested	Number of IRCCs with cycle data	Number of IRCCs without any cycle data	% of IRCCs without any cycle data
Estonia	287	28	259	90%
Germany	11,579	8,241	3,338	29%
Portugal	15,598	14,404	1,194	8%
Slovenia	3,553	3,086	467	13%
Total	31,017	25,759	5,258	17%

Treatment outcomes recorded



	Number of pregnancies	Number of miscarriages	Number of deliveries	Number of live born children
Estonia	10	0	6	8
Germany	1,658	371	896	930
Portugal	2,293	394	1,165	1,207
Slovenia	476	43	222	222
Total	4,437	808	2,283	2,359

Parameters with less than 50% completion



- 13. Treatment protocol
 - Type of gonadotropin (if used)
 - Trigger used for final oocyte maturation
 - Luteal support
 - Luteal support prescribed until
 - Other
- 20. Reason for oocyte cryopreservation
- 23. c. Age of donor at time of oocyte collection (in case donor oocytes were used)
- 24. Date of insemination
- 34. Reason for embryo cryopreservation
- 44. Luteal support in FET
- IUI cancelled
- IUI cancellation causes
- 53. Details of twin pregnancy
- 53. Details of twin pregnancy a. Diamniotic detail
- 54. Fetal reductions
- Child 1 Neonatal outcome (routine care or ICU)
- Child 2 Neonatal outcome (routine care or ICU)



What **professionals** thought of EuMAR

From a **survey** with 34 responses sent to participating MAR centres in all pilot countries

Learnings from all pilot countries




Overall, how satisfied are you with the pilot study?



Learnings from all pilot countries

I would be willing to participate in the EuMAR Registry in the long term beyond the pilot study.



Learnings and challenges



We have **positive** outcomes from the pilot study, but we also encountered some challenges

1. **Approvals** needed at national level cause delays

2. Different **interpretations of legal basis** led to different use of consent forms and changes in internal structure

Involvement of **different stakeholders**, including authorities, clinics and patients is necessary for accurate cumulative and cross-border data

COMPLIANCE

ENGAGEMENT

TECHNICAL

IT connections for automatised data submission are a **long and costly process**

WP6 members



Christian De Geyter
WP6 Leader



Carlos Calhaz-Jorge
WP6 Member



Veerle Goosens
Project Support



Elena Achótegui Sebastián
Project Support



Johanna Tassot
Project Support



Rob Goijen (eFertility)
WP6 Member



Andreas Tandler-Schneider
WP6 Member
Germany



Markus Kimmel
WP6 Member
Germany



Patrícia Silva
WP6 Member
Portugal



Borut Kovačič
WP6 Member
Slovenia



Tuuli Dmitrijeva
WP6 Member
Estonia



Karin Rosenstein
WP6 Member
Estonia

Thank you!



#EuMAR25



www.eshre.eu/Data-collection-and-research/EuMAR
European Society of Human Reproduction and Embryology



Session 3:

Outcomes

Updated parameters and definitions

Jesper Smeenk

Brussels, Friday 12 December 2025



Co-funded by the European Union.

Project: 101079865 — EuMAR — EU4H-2021-PJ2



WP4 : Selection and definition of parameters



Aims

- Identify and define relevant MAR parameters, including fertility preservation (Objective 1)

Specific aims

- To identify relevant items to be registered taking into account the different stakeholders (tissue establishments, country, and EU competent authorities ensuring surveillance and biovigilance, patients/donors).
- To create a glossary of standardised definitions in order to ensure proper data harmonisation.

Tasks



WP4 : Selection and definition of parameters




Characteristics and parameters with accepted terminology

Q4 2023

Stakeholder event 05 December 2023

Update Characteristics and parameters with accepted terminology

Stakeholder event 12 December 2025



Deliverables

D4.1 - Characteristics and parameters with accepted terminology

Parameters – set-up and after revision

Part 1: Parameters to be included in the register

Module 1 – Identification
Module 2 – Patient variables
Module 3 – Cycles with ovarian stimulation
Module 4 – Laboratory data
Module 5 – Embryo transfer
Module 6 – Complications during pregnancy
Module 7 – Pregnancy and outcome
Module 8 – IUI
Module 9 – Fertility preservation

Part 2: Parameters to be derived from the register

9 Modules
64 Parameters

Usability EuMAR parameters



HARMONISATION is KEY

Developing a parameter list → not reinvent the wheel



EDQM

EuMAR parameters were based on EDQM exercise on harmonising activity data collection in the field of tissues and cells with intention to take up the role of an international registry


ICMART

The glossary was the starting point for the EuMAR definitions

National Registers

Served as a library of parameters already collected in different countries

What happened after December 2023?




Module 1 – Identification



1. EuMAR IRCC
2. Cycle identification Improve list as follows:

- a. FRESH cycle with own gametes
- b. FRESH cycle with donated gametes
- c. Frozen-thawed embryo transfer (FET) cycle with own gametes
- d. Frozen-thawed embryo transfer (FET) cycle with gamete/embryo donation
- e. Intra-uterine insemination (IUI) with partner gametes
- f. Intra-uterine insemination (IUI) with donor gametes
- g. Fertility Preservation (FP)



- a. IVF, ICSI, IVF+ICSI cycle (aim: fresh cycle)
- b. Frozen-thawed embryo transfer (FET) cycle
- c. Combination of IVF/ICSI + FET cycle
- d. Fertility Preservation (FP)
- e. Intra-uterine insemination (IUI)
- f. Oocyte donation/ sperm donation
- g. In Vitro Maturation (IVM) cycle

Module 2 – Patient variables



3. Country of current residence
4. Female Date of Birth
5. Female Body Mass Index (BMI)
6. Female current smoking status
7. Male Date of Birth
8. Male Body Mass Index (BMI)
9. Male current smoking status

Body Mass Index main patient

DELETE

DELETE

DELETE



10. Indication for treatment

simply list as follows:

- a. Unexplained infertility
- b. Tubal pathology
- c. Ovulatory disorder
- d. Endometriosis/adenomyosis
- e. Psychosexual (can be an indication for IUI and occasionally IVF)
- f. Premature Ovarian Insufficiency (POI)/oocyte issue (women who need donor eggs)
- g. Sperm factor
- h. No sperm provider (same-sex or singles)
- i. No egg provider (same-sex or singles)
- j. Need for Preimplantation Genetic Testing (PGT)

Module 3 – Cycles with ovarian stimulation



11. Ovarian Stimulation
12. Date of start cycle
13. Treatment protocol
14. Cancellation prior to Ovum Pick Up (OPU)
15. OPU cancellation cause
16. Date of ovum pick-up
17. Number of cumulus oocyte complexes retrieved
18. In-vitro maturation **DELETE, now part of identification in Module 1**
19. Number of oocytes cryopreserved
20. Reasons for oocyte cryopreservation **ADD Duostim**
21. Number of oocytes donated

Module 4 – Laboratory data



- 22. Source of sperm
- 23. Source of oocytes
- 24. Date of insemination
- 25. Insemination technique
- 26. N of oocytes inseminated (IVF)
- 27. N of oocytes injected (ICSI)
- 28. N of 2 pronuclei (2pn) – IVF
- 29. N of 2pn – ICSI
- 30. N of embryos developed (IVF and ICSI)


Parameters remain the same

Module 4 – Laboratory data



- 31. Total N of embryos cryopreserved
- 32. Optional: N of cleavage stage embryos cryopreserved
- 33. Optional: N of blastocysts cryopreserved
- 34. Reasons for embryo cryopreservation
- 35. Pre-implantation Genetic Testing

Improve list to following:



- a. Supernumerary embryos
- b. PGT
- c. Medical reason
 - OHSS risk
 - Infection
 - Intercurrent disease
 - Fertility preservation
 - Uterine or tubal pathology undiagnosed before cycle start
 - other
- d. Non-medical reason
 - Religion
 - Legal issues
 - other
- e. Planned freeze all (for autologous use /not for fertility preservation)
- f. Donation

Modules 5 – Embryo transfer



36. Embryo transfer

37. Embryo transfer with:

- a. Fresh embryos
- b. Frozen **own** embryos
- c. Frozen **donated** embryos
- d. Combination of fresh and frozen embryos

Use of fresh embryos

38. Date of embryo transfer

39. Number of cleavage **or morula** stage embryos transferred

40. Number of blastocysts transferred.

41. Embryo Transfer Outcome

Modules 5 – Embryo transfer



Use of frozen embryos

42. Date of thawing

43. Frozen embryo transfer protocol (FET)

44. Embryo Transfer

45. Date of embryo transfer (link to OPU if available)

Insert

- Date from cycle from which the embryo originate
- Number of thawed cleavage or morula stage embryos
- Number of thawed blastocysts

46. Number of cleavage or morula stage embryos transferred

47. Number of blastocysts transferred

48. Embryo Transfer Outcome

49. Cause of no embryo transfer

- a. No embryos (failed fertilisation/failed cleavage/abnormal embryos)
- b. No embryos (failed thawing)
- c. Cryopreservation

Modules 6 - Complications



50. Complications

51. Causes

Improve list as follows, adhering to GDPR:

- a. OHSS Severe (Grade III – IV or hospitalization for lesser grades)
- b. Infection
- c. Bleeding requiring hospitalization, blood transfusion and/or surgery
- d. Thrombosis
- e. Ovarian or adnexal torsion **NEW**
- f. Other

Modules 7 – Pregnancy and outcome

- 52. Highest number of intra-uterine gestational sacs on ultrasound scan
- 53. Details of twin pregnancy
- 54. Fetal reductions
- 55. Pregnancy outcome
- 56. Date of delivery
- 57. N of children born Alive and dead
- 58. N of stillbirths DELETE

Liveborn Child 1

- 59. Sex
 - 60. Birth weight
 - 61. Neonatal outcome
 - 62. Neonatal malformations
- Questions for every liveborn child

Modules 8 & 9 – IUI – Fertility preservation



- 61. IUI cancelled
- 62. Outcome

- 63. Method of fertility preservation
- 64. Reason for fertility preservation

a. Medical

- 1. Oncology
- 2. Benign medical conditions (eg endometriosis, benign haematological disorders in children, Surgical risk for later infertility..)
- 3. Gender transition
- 4. Differences in Sex Development (DSD)

b. Non-medical

To be expanded for collection of use of material in the future

Parameters to be calculated



Part 2: Parameters to be derived from the register

Part 2: Number of Parameters

25 parameters

Totals
Timeframes
Rates
Cumulative rates



# of treated individuals	# of individual persons that had at least one treatment cycle intervention (IUI, IVF/ICSI and/or FET) completed
Age of the individual	Date of start cycle minus date of birth
# of couples that had at least one treatment cycle intervention (IUI, IVF/ICSI and/or FET) completed	# of couples that had at least one treatment cycle intervention (IUI, IVF/ICSI and/or FET) completed
# of treatment cycles without stimulation	# of cycles without ovarian stimulation (includes hormone substituted cycles) that ended up with one of the interventions
Cumulative pregnancy rate	The number of oocyte retrievals resulting in at least 1 clinical pregnancy within 1 year of the oocyte retrieval cycle divided by the total number of oocyte retrieval cycles that had at least 1 fresh or frozen embryo transfer

WP4 members



Veerle Goossens
Project Support
Belgium



Jesper smeenk
WP Leader
The Netherlands



Nathalie Vermeulen
WP4 Member
Belgium



Christina Bergh
WP4 Member
Sweden



Janos Urbancsek
WP4 Member
Hungary



Mary Wingfield
WP4 Member
Ireland



Mika Gissler
WP4 Member
Finland



Borut Kovacic
WP4 Member
Slovenia



Roberto De Luca
WP4 Member
Italy



Dashboards: features and KPIs

Christine Wyns

Brussels, Friday 12 December 2025




Co-funded by the European Union.

Project: 101079865 — EuMAR — EU4H-2021-PJ2



Introduction



Benefits of EuMAR



**Monitoring of trends and
treatment outcomes in
MAR**



**Patient
reports**




Dashboards

**Collection and calculation
of cumulative outcome
parameters**



**Harmonised data
from EU countries**



**Inter-institutional
and cross-border data
collection**



**Data for Open
Science**



**Quality assurance and
benchmarking for clinics**



Benefits of EuMAR: dashboards



Objective:
Transparency for informed decision-making

→ Present QI/KPIs

→ Benchmark against relevant stakeholders



Quality indicators (QI)- KPIs



QI = tool to **quantify the quality of a selected aspect of care**

= objective measure that evaluates critical healthcare domains (**safety, effectiveness, equity**, patient-centeredness, timeliness, efficiency)

→ **specifications** for the numerator, denominator and data collection requirements

→ **consistent and comparable** across settings and over time

→ **tailored to objectives and stakeholders**

Designing and tailoring towards objectives



What we want to see presented in the dashboards:

EIM data



Reproduce at least the data as published in the yearly reports

Cumulative data



Cross Border data



The presented data need to fit the **audience**



Data visualisation tailored to audience

Clinicians and MAR centers

National Registers/Competent Authorities

Researchers

Patients/general public

EU Stakeholders

Data visualisation: type by stakeholder

Clinicians and MAR centers	<ul style="list-style-type: none">• Cycle by cycle data from own centre• Benchmark against national values
National Registers/Competent Authorities	<ul style="list-style-type: none">• Aggregated data• Cycle by cycle data for specific country• Benchmark against other Member States
Researchers	<ul style="list-style-type: none">• Aggregated data• Specific data upon request
Patients/General Public	<ul style="list-style-type: none">• Aggregated data
EU Stakeholders	<ul style="list-style-type: none">• Aggregated data

Development of dashboards content

WP5: Brainstorm on content + IT: transform ideas in output

Dashboards populated with data from the pilot study:

- only limited data/concerns with missing's
- not all features/data can be used

Under development: cumulative data and benchmarking


When dashboard is populated with more data, send to test audience

- feedback on user friendliness and completeness
- suggestions for improvement

Output




DEMO

 All Cycles

 IVF/ICSI Cycles

 Fertility Preservation Cycles

 FET Cycles


 PGT Cycles





EuMAR
by ESHRE


**Explore Fertility Treatment
Processes With Easy Access to Data**

Please choose a dashboard page

 Ovarian Stimulation

 Lab Results

 ART Pregnancies

 IUI Pregnancies

Last Data Updates
Click to view the latest data update dates for each center.

Benchmarking Page
Click to view the benchmarking report to compare clinics.

Availability if >80% completeness

Type of benchmarking e.g. based on size of clinics

Output



Home > All Cycles

DEMO

Hide Values

Clear All

Year of Cycle

Alle

Type of Cycle

Alle

Origin of Sperm

Alle

Freeze All

Alle

Type of Oocyte

Alle

Origin of Oocyte

Alle

More Filters (2)

Shortcuts

IVF/ICSI Cycles

IUI Pregnancies


Fertility Preservation Cycles

FET Cycles


PGT Cycles

ART Pregnancies

Cycles and Patients



Cycles Per Cycle Type



26.4K

Number of Cycles between 2023 - 2025

23.4K

Number of Patients Treated between 2023 - 2025

Output



Home > All Cycles

DEMO

Hide Values

- ☐ Alles selecteren
- ☐ (Leeg)
- ☐ Fertility Preservation
- ☐ FET
- ☐ IUI
- ☐ IVF/ICSI
- ☐ IVM
- ☐ PGT

- ☐ Alles selecteren
- ☐ (Leeg)
- ☐ donor sperm
- ☐ partner sperm (own sperm)

Year of Cycle

Alle

Type of Cycle

Alle

Origin of Sperm


Alle

- ☐ Alles selecteren
- ☐ (Leeg)
- ☐ donor sperm
- ☐ partner sperm (own sperm)


Shortcuts

- IVF/ICSI Cycles
- IUI Pregnancies
- Fertility Preservation Cycles
- FET Cycles
- PGT Cycles
- ART Pregnancies

Cycles and Patients



Cycles Per Cycle Type



26.4K

Number of Cycles between 2023 - 2025

23.4K

Number of Patients Treated between 2023 - 2025



Output



Home > **Ovarian Stimulation**

DEMO

[Clear All](#)

Type of Cycle

Alle

Insemination Technique

Alle

Origin of Sperm

Alle

Origin of Oocyte

Alle

Type of Oocyte

Alle

Patient Age

15


60

[More Filters \(2\)](#)


Shortcuts

IVF/ICSI - Cycles


Pre-Treatment Protocol





LH Suppression Protocol



Stimulation Drug



Gonadotropin Type



Output



Home > Ovarian Stimulation

DEMO

- ☐ Alles selecteren
☐ (Leeg)
☐ ICSI
☐ IVF
☐ Mixed IVF and ICSI

- ☐ Alles selecteren
☐ (Leeg)
☐ donor sperm
☐ partner sperm (own sperm)

Type of Cycle

Alle

Insemination Technique

Alle

Origin of Sperm

Alle


Origin of Oocyte

Alle


- ☒ Alles selecteren
☒ (Leeg)
☒ fresh
☒ frozen

Clear All


Pre-Treatment Protocol





LH Suppression Protocol



Stimulation Drug



Gonadotropin Type



Output



Home > Lab Results

DEMO

Clear All

Type of Cycle
Alle

Origin of Sperm
Alle

Type of Sperm
Alle

Sperm Collection Method
Alle

Origin of Oocyte
Alle


Patient Age
15 70

More Filters (5)

Shortcuts


- All Cycles
- IVF/ICSI - Cycles
- IVF/ICSI - Cancellation
- IVF/ICSI - Pregnancies

Fertilization




Embryo Utilization per Oocyte

Part of retrieved oocytes that is used for embryo transfer or oocyte/embryo cryopreservation




Oocyte to Embryo Funnel



Embryo Utilization per 2PN

Part of 2PN zygotes that is used for embryo transfer or embryo cryopreservation



Output



Home > Lab Results

DEMO

- ☐ Alles selecteren
☐ (Leeg)
☐ donor sperm
☐ partner sperm (own sperm)

- ☐ Alles selecteren
☐ (Leeg)
☐ fresh
☐ frozen

Type of Cycle
Alle


Origin of Sperm
Alle

Type of Sperm
Alle

Sperm Collection Method
Alle
☐ Alles selecteren
☐ (Leeg)
☐ combination of ejaculatio...
☐ ejaculation
☐ retrograde ejaculation
☐ surgical retrieval


All Cycles
IVF/ICSI - Cycles
IVF/ICSI - Cancellation
IVF/ICSI - Pregnancies

Fertilization




Embryo Utilization per Oocyte

Part of retrieved oocytes that is used for embryo transfer or oocyte/embryo cryopreservation




Oocyte to Embryo Funnel



Embryo Utilization per 2PN

Part of 2PN zygotes that is used for embryo transfer or embryo cryopreservation



Output



Home > ART Pregnancies

DEMO

Clear All

Type of Cycle

Alle

Insemination Technique

Alle

Origin of Sperm

Alle

Type of Sperm

Alle

Sperm Collection Method

Alle

Patient Age

18

50


More Filters (4)

Shortcuts


IVF/ICSI - Pregnancies

FET Cycles


Clinical Pregnancies Per Transfer




Implantations Per Embryo Transferred



Twin Pregnancies



Triplet Pregnancies



76.4K

Number of Cycles between 2023 - 2025

35.8K

Number of Patients Treated between 2023 - 2025

Output



Home > ART Pregnancies

DEMO

Clear All

Type of Cycle
Alle

Insemination Technique
Alle

Origin of Sperm
Alle

Type of Sperm
Alle

Sperm Collection Method
Alle

Patient Age
18 50

- ☐ Alles selecteren
- ☐ (Leeg)
- ☐ ejaculation
- ☐ retrograde ejaculation
- ☐ surgical retrieval

More Filters (4)

Shortcuts

- IVF/ICSI - Pregnancies
- FET Cycles

Filter Pane X

Country Name
Alle



Year of Cycle
Alle

Origin of Oocyte

- ☐ Alles selecteren
- ☐ (Leeg)
- ☐ donor oocytes
- ☐ own oocytes

Type of Oocyte
Alle

Clear Close





76.4K

Number of Cycles between 2023 - 2025

35.8K

Number of Patients Treated between 2023 - 2025



Output



Home > **Benchmarking**

DEMO

Clear All


Year of Cycle

Alle

Shortcuts

All Cycles

Fertilization Rate Per Injected Oocyte



Where to find the dashboards



Only data from pilot study – no conclusions can be drawn at this time

- Centres/national authority-registers collaborating in the pilot study:
Log-in to the platform
- General public/patients, once ready:
ESHRE webpage EuMAR

Home / Data collection / EuMAR

European monitoring of Medically Assisted Reproduction

EuMAR is a three-year project (2023-2025), co-funded by the EU4Health program at the European Commission (DG SANTE) and run by ESHRE. Its aim is to develop a pan-European registry of prospective cycle-by-cycle data on the use and outcomes of medically assisted reproduction (MAR) treatments. EuMAR addresses the need for:

- Transparency and accessibility of data
- Quality assurance and surveillance
- Standardisation of parameters and definitions for comparability of data
- Flexibility to connect to other registries in the future
- The possibility to calculate cumulative outcomes and understand cross-border care trends
- A patient-centred approach, where patients' perspectives are heard, and they have power over their own treatment data

Objective 1: Construction of a data flow system beneficial to all stakeholders

Objective 2: Standardisation and definition of precise MAR parameters

Objective 3: Development of a technical solution and introduction of a coherent coding system for the prospective follow-up of reproductive care

EuMAR by ESHRE

An 'overarching', standardised, web-based data registry in MAR in the European Union

Co-funded by the European Union.
Project: 101079865 - EuMAR - EU4H-2021-PJ2
Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union. Neither the European Union nor the granting authority can be held responsible for them.

WP5 members



Veerle Goossens
Project Support
Belgium



Christine Wyns
WP Leader
Belgium



Christian De Geyter
WP5 Member
Switzerland



Irena Antonova
WP5 Member
Bulgaria



Jean Calleja Agius
WP5 Member
Malta



Irene Cuevas
WP5 Member
Spain



Diane De Neubourg
WP5 Member
Belgium



Bogdan Doroftei
WP5 Member
Romania



Karel Rezabek
WP5 Member
Czech Republic



Giulia Scaravelli
WP5 Member
Italy



Rob Goijen (eFertility)
WP5 Member
Netherlands



Rutger Slager (eFertility)
WP5 Member
Netherlands



Luc Vanoppen
WP5 Member
Belgium



Ruben Roex (Timelex)
WP5 Member
Belgium

Thank you!




EuMAR

by ESHRE



#EuMAR25



www.eshre.eu/Data-collection-and-research/EuMAR

European Society of Human Reproduction and Embryology



Session 4:

Looking ahead

Next steps: EuMAR 2

Jesper Smeenk

Brussels, Friday 12 December 2025



Co-funded by the European Union.

Project: 101079865 — EuMAR — EU4H-2021-PJ2





EuMAR 2

- EuMAR 2 is proposed as a **two-year extension** of the project (2026-2028)
- Its **aims** are to bridge the gap between the current pilot project and a fully operational, sustainable European cycle-by-cycle MAR registry
- EuMAR 2 will be entirely **funded by ESHRE**



EuMAR 2 aims

1. **Refine** registry **processes** and **features** built in EuMAR 1
2. Ensure **credibility** and **value** of the data for stakeholders
3. Foster **connectivity** across countries and MAR centres

Aim 1: Refine processes



Further test inter-institutional & cross-border data collection



Clearly establish GDPR compliance



Plan transition from pilot phase to operational registry



Aim 2: Ensure value



High-quality data
collection &
governance



Implementation of
updated
parameters



Beneficial outputs
for patients, clinics,
policymakers,
researchers



Aim 3: Foster connectivity



Connect up to ten countries by the end of 2027



Promote registry benefits & continue promoting engagement with stakeholders



Develop a sustainability plan that includes integration with EIM & potential external funding opportunities





Project structure

WP Project Management

The activities related to planning, organising, monitoring and managing the resources and tasks necessary to achieve the project goals in an effective and efficient way.

WP2 Communications

Ensure the correct flows of information to prevent misunderstandings, keep a team cohesion; and reach external stakeholders, to deliver the right message and maximise engagement.


WP3 Data Registry

Logistical and technical aspects of maintaining and expanding the EuMAR registry. It is divided into WP3.1 Data Input and Expansion, WP3.2 Data Processing & Quality Assurance, and WP3.3 Data Output and Utilisation.

WP4 Sustainability

As a bridge between a project activity and an operational activity, EuMAR 2 will define key aspects that will support the future sustainability of the registry.

EuMAR 2 governance



Expected outcomes



1

Broad **recognition of the EuMAR registry** and its value across all key stakeholder groups

2

Fully **operational online platform** connected to 10 countries

3

A validated **solution for cumulative and cross-border data collection**

4

Benchmarking tool for centres to support high-quality MAR care

Expected outcomes



5

Transparent and **informed decision-making** (from the public dashboards)

6

Greater data literacy and data awareness through standardised **patient reports**

7

Formal **recognition for participating centres** (EuMAR contributor certificates)

8

Solid **sustainability** and operational plans


Potential of the EuMAR registry



Incorporation of innovation




Changing EuMAR parameters



Incorporation of innovation




Changing EuMAR parameters



Incorporation of innovation



Connecting to non-MAR national and international



EuMAR – SoHO connection



EuMAR could provide standardised reports for clinics to facilitate the submission of the annual activity data report that NCAs will need to upload to the SoHO Platform (based on Article 31, SoHO Regulation).

The **exact SoHO parameters are not yet known**, therefore, it is not possible to define exactly how EuMAR can support clinics and NCAs with the mandatory activity data reporting towards the SoHO Platform.

However, the use of EuMAR consent will mean that EuMAR data may not cover 100% of cycles from the reporting country, limiting this option.

Looking ahead: The importance of Registries in the SoHO Regulation

Rita Piteira – SoHO Team


12th December 2025

New Concepts


SoHO Entities & SoHO Preparations



SoHO entities Vs. SoHO establishments



Supervision of all SoHO Activities that directly impact safety, quality or effectiveness




Any actor organising one or more SoHO activity/ies needs to
register as SoHO entity with the Competent Authority

General Obligations of SoHO Entities

- Registration
- Responsible person
- Quality Management System
- Activity data Collection
- SoHO Preparation + Authorisation
- SoHO Clinical Studies
- Traceability and coding
- Vigilance and Reporting



SoHO Preparations



SoHO Preparations^{NEW}

Present

Authorisation of SoHO **Activities**,
as part of authorisation of
blood/tissue establishments
(information on SPs is not
(generally) available)

2026

Migration of information related to
existing **preparations** (SPs)
(SoHO Entities → CAs →
Platform) (GAPP Pro Survey?)

Information related to novelty and
risk and additional information
(when applicable, based on
EDQM Monographs and Risk
Assessment)

August 2027

Authorisation of SoHO **Activities**
and **Preparations**:

- PPD Template and associated
procedures (GAPP + GAPP
Pro), validated by SCB
- New SoHO Preparations (SP)
will require SPA and data
registration in the SoHO
Platform
- Information to be shared
among CAs (when applicable
and as appropriate)
- best practices documented and
published by the SCB (Art 69(1)
and 19(4))



SoHO Preparations Authorisation



Taking into account any relevant EDQM monograph

- 1 Systematic Benefit:Risk Assessment to determine the evidence available on safety, quality and effectiveness
- 2 Submission of an application, including laboratory validation and other safety, quality and effectiveness data and, where relevant, a clinical outcome monitoring plan proportionate to risk
- 3 Assessment of the application by the competent authority

Grant authorisation for the SoHO preparation

OR

Grant an approval of the Clinical Outcome Monitoring plan or request an amended plan

OR

Refuse authorisation

- 4 Assessment by the competent authority of evidence of safety, quality and effectiveness data gathered in clinical outcome monitoring

Grant authorisation

OR

Refuse authorisation

SoHO Preparations




Figure 1. The extent of plan for collecting clinical data included in the clinical component of the PPD is based on the risk level.

Ref: GAPP JA - Technical Annex 3 to overall guidance: assessing clinical data as part of Preparation Process Authorisation (PPA)




SoHO Platform



SoHO Platform



SoHO Platform



SPA Module – SoHO Platform



Dataset



Monographs



Structure and methodology



SPA Module – Key considerations

- **Compendium of information:**
 - (with different levels of access: Applicant and CA > Cooperating CA > Public (other entities))
 - (Future) PPD functionalities
 - Information related to the extent of evidence (clinical and non clinical) – **Use of Registries!**
- Based on data introduced by the applicant (SoHO – E) and validated by the CA



SPA Module – SoHO Platform





Figure 1. The extent of plan for collecting clinical data included in the clinical component of the PPD is based on the risk level.

Ref: GAPP JA - Technical Annex 3 to overall guidance: assessing clinical data as part of Preparation Process Authorisation (PPA)




SPA Module – SoHO Platform



European
Commission

**SoHO
Platform**




My Dashboard

SEC Lookup

Compendia ▾

Guidelines ▾

 Rita PITEIRA ▾

[Home](#) > SoHO Preparation Details**Lyophilized Amniotic Membrane**

Details of the PPA

EUTC Code:
*MEMBRANE, AMNIOTIC***Novelty Status (1):**
*Established in EDQM Monograph***Monograph reference :**
*20.1. Amniotic membrane sheet***Novelty Status (2):**
*SP has been previously authorised (before Aug 2027)***Status:**
Verified

Clinical Indication #1Clinical Indication #2

Back

Clinical Indication Details

Fully authorised (issuing date)

Malignant neoplasms of eye or ocular adnexa
BlockL3-2D0**Clinical Indication Description:**

- Ophthalmic use in patients with epithelial defects of the cornea or conjunctiva: corneal ulcers, acute chemical burns, large conjunctiva! resections
- Coadjuvant in corneal transplantation and in cases where tissue regeneration or postoperative healing problems are expected

Key clinical benefits of the SoHO Preparation:
<None>**Alternative therapies of SoHO, if any:**
<None>**Novelty in clinical**
—


SoHO Platform




Article 41

- SoHO entities shall collect and report data relating to any of the following SoHO activities
 - (a) SoHO donor registration
 - (b) collection
 - (c) distribution
 - (d) import
 - (e) export
 - (f) human application
- Considerations:
 - EU-wide, all X,000 SoHO entities, per SoHO
 - annual exercise, possible use of registries, recycle existing data exercises


Digital flow entity/establishment (SoHO E) data submission



Digital flow entity/establishment (SoHO E) data submission



Thank You



rita.PITEIRA@ec.europa.eu



Thank you!



EuMAR

by ESHRE



#EuMAR25



www.eshre.eu/Data-collection-and-research/EuMAR

European Society of Human Reproduction and Embryology



Session 4:

Final Remarks

European Medically Assisted Reproduction registry Final Dissemination Conference

Final remarks

Carlos Calhaz-Jorge



Co-funded by the European Union.

Project: 101079865 — EuMAR — EU4H-2021-PJ2



Final remarks



EuMAR

a pan-European cycle-by-cycle MAR registry

- Will rely on the participation of CA, professionals and patients
- Will empower patients
- Will be a crucial contribution for improving clinical care

EuMAR policy recommendations



Improve equitable
access to fertility
care

Collect MAR
Equality data

Ensure national
mandatory
reporting from all
clinics

For MS

Provide dedicated
funding for EuMAR
reporting

Develop a legal
framework for a
gamete donor
registry

Make cycle-by-
cycle MAR
registries
mandatory

For EU

Raise patients'
awareness on MAR
data

For EU & MS

